Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

OMA102

Phase 3Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Female Pattern Hair LossNot yet recruiting

Female Pattern Hair LossPhase 3

Not yet recruiting

Timeline

Expected Milestones

Q1 2027

Phase 3Not yet recruiting

Female Pattern Hair Loss

NCT05824065

Clinical

Trials by Indication[1]

Female Pattern Hair Loss1 trial

Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss

Not yet recruiting·EEMS·Phase 3·NCT05824065·504 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OMA102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OMA102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OMA102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEMS

Related News